Clinical utility of micafungin: pharmacokinetics, dosing, use in special populations and drug interactions

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Mycoses

• Publication date

  2012-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1439-0507.2011.02114.x
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Lack of Pharmacokinetic Drug Interaction Between Oral Posaconazole and Caspofungin or Micafungin

  2011cited by this paper
• Distribution of micafungin in the tissue fluids of patients with invasive fungal infections

  2011cited by this paper
• Pharmacodynamics of Echinocandins against Candida glabrata: Requirement for Dosage Escalation To Achieve Maximal Antifungal Activity in Neutropenic Hosts

  2011cited by this paper
• Disseminated Candidiasis Caused by Candida albicans with Amino Acid Substitutions in Fks1 at Position Ser645 Cannot Be Successfully Treated with Micafungin

  2011cited by this paper
• Intraocular Penetration of Micafungin in Patient with Candida albicans Endophthalmitis

  2011cited by this paper
• Breakthrough Invasive Candidiasis in Patients on Micafungin

  2010cited by this paper
• Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.

  2010cited by this paper
• Safety and Pharmacokinetics of Repeat‐Dose Micafungin in Young Infants

  2010cited by this paper
• Intrapulmonary Pharmacokinetics and Pharmacodynamics of Micafungin in Adult Lung Transplant Patients

  2010cited by this paper
• Micafungin Concentrations from Brain Tissue and Pancreatic Pseudocyst Fluid

  2010cited by this paper
• In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species

  2010cited by this paper
• Population Pharmacokinetics of Micafungin in Neonates and Young Infants

  2010cited by this paper
• Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

  2009cited by this paper
• Pharmacokinetics of an Elevated Dosage of Micafungin in Premature Neonates

  2009cited by this paper
• The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates.

  2008cited by this paper
• In Vivo Pharmacodynamic Target Investigation for Micafungin against Candida albicans and C. glabrata in a Neutropenic Murine Candidiasis Model

  2008cited by this paper
• Bronchopulmonary Disposition of Micafungin in Healthy Adult Volunteers

  2008cited by this paper
• Population pharmacokinetics of micafungin in adult patients.

  2008cited by this paper
• Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.

  2007cited by this paper
• Population Pharmacokinetics of Micafungin in Pediatric Patients and Implications for Antifungal Dosing

  2007cited by this paper
• Caspofungin in the treatment of symptomatic candiduria.

  2007cited by this paper
• Micafungin does not influence the concentration of tacrolimus in patients after allogeneic hematopoietic stem cell transplantation.

  2007cited by this paper
• The Pharmacokinetics and Safety of Micafungin, a Novel Echinocandin, in Premature Infants

  2006cited by this paper
• Once-Weekly Micafungin Therapy Is as Effective as Daily Therapy for Disseminated Candidiasis in Mice with Persistent Neutropenia

  2006cited by this paper
• A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation

  2006cited by this paper
• Steady-State Pharmacokinetics of Micafungin and Voriconazole after Separate and Concomitant Dosing in Healthy Adults

  2006cited by this paper
• Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis

  2006cited by this paper
• Concomitant Tacrolimus and Micafungin Pharmacokinetics in Healthy Volunteers

  2005cited by this paper
• Pharmacokinetic and Maximum Tolerated Dose Study of Micafungin in Combination with Fluconazole versus Fluconazole Alone for Prophylaxis of Fungal Infections in Adult Patients Undergoing a Bone Marrow or Peripheral Stem Cell Transplant

  2005cited by this paper
• Safety, Tolerability, and Pharmacokinetics of Micafungin (FK463) in Febrile Neutropenic Pediatric Patients

  2005cited by this paper
• Pharmacodynamics of Caspofungin in a Murine Model of Systemic Candidiasis: Importance of Persistence of Caspofungin in Tissues to Understanding Drug Activity

  2005cited by this paper
• Concomitant Cyclosporine and Micafungin Pharmacokinetics in Healthy Volunteers

  2005cited by this paper
• Pharmacokinetics of Micafungin in Healthy Volunteers, Volunteers With Moderate Liver Disease, and Volunteers With Renal Dysfunction

  2005cited by this paper
• Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. Isolates

  2005cited by this paper
• Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation.

  2004cited by this paper
• Echinocandin antifungal drugs.

  2003cited by this paper
• Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin.

  2003cited by this paper
• From natural products to clinically useful antifungals.

  2002cited by this paper
• Comparative Antifungal Activities and Plasma Pharmacokinetics of Micafungin (FK463) against Disseminated Candidiasis and Invasive Pulmonary Aspergillosis in Persistently Neutropenic Rabbits

  2002cited by this paper
• Compartmental Pharmacokinetics and Tissue Distribution of the Antifungal Echinocandin Lipopeptide Micafungin (FK463) in Rabbits

  2001cited by this paper

• Microbial Control of Leptopharsa heveae Drake & Poor (Hemiptera: Tingidae) in Brazilian Rubber Tree Plantations: a Brief Historical Account and Identification of Entomopathogenic Fungi by Means of Multigene Phylogeny

  2020cites this paper
• Population Pharmacokinetics of Micafungin and Its Metabolites M1 and M5 in Children and Adolescents

  2014cites this paper